Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting

1 min read

The FINANCIAL — At a meeting on May 17 with industry analysts, senior leaders of Johnson & Johnson and its Janssen Pharmaceutical Companies will announce plans to launch or file for regulatory approval more than 10 new products with blockbuster potential between 2017 and 2021, as well as 50-plus line extensions of existing and new medicines that will bring the company’s transformational medicines to an even broader patient population.

The company will also share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the industry-leading productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion.

“With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our pharmaceutical business will continue to be a significant driver of innovation and growth for Johnson & Johnson. With our proven global commercial capabilities and robust pipeline, we are well-positioned to continue delivering strong, long-term, sustainable growth.”

An industry leader in research productivity, Janssen has received US FDA approval for 11 new molecular entities (NMEs) since 2011. With a portfolio focused on five core therapeutic areas – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism, and Oncology – the Pharmaceutical segment of Johnson & Johnson is delivering transformational new medicines for unmet medical needs worldwide, and expects to add a sixth therapeutic area in Pulmonary Arterial Hypertension upon the completion of the acquisition of Actelion, which is expected to close by the end of the second quarter, according to Johnson & Johnson.

In 2016, the company filed two NMEs that it anticipates will be approved and launched later this year:

guselkumab for psoriasis; and

sirukumab for rheumatoid arthritis.

Additional late-stage blockbuster products1 projected to file for regulatory approvals between 2017 and 2021, include:

apalutamide (ARN-509) for pre-metastatic prostate cancer;

esketamine for treatment-resistant depression;

talacotuzumab (CSL362) for acute myeloid leukemia;

erdafitinib (FGFR Inhibitor) for solid tumors;

niraparib for prostate cancer;

imetelstat for myelofibrosis;

pimodivir (JNJ-3872) for influenza A;

lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection; and,

JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for major depressive disorder.


Leave a Reply